Latigo Biotherapeutics Reports $25.8 Million Net Loss in Q2 2026, Advances Onzotrigine Trials

Latigo Biotherapeutics, Inc. reported a net loss of $25.8 million for the second quarter of 2026, slightly down from a loss of $25.8 million in the same period of 2025. For the first half of 2026, the company recorded a net loss of $48.8 million, compared to $46.8 million for the first half of 2025. The company’s accumulated deficit reached approximately $291.9 million as of June 30, 2026. Total operating expenses for the second quarter were $25.8 million, a marginal increase from $25.7 million in the prior year, driven primarily by a rise in general and administrative expenses, which increased to $4.6 million from $2.8 million year-over-year.

In terms of financial position, Latigo's cash and cash equivalents decreased to $55.0 million from $69.4 million at the end of 2025. The company’s total liabilities rose significantly to $52.3 million from $18.6 million at the end of the previous fiscal year, largely due to the issuance of $35 million in convertible promissory notes in June 2026. The company also reported a total stockholders' deficit of $276.1 million as of June 30, 2026, compared to $231.7 million at the end of 2025.

Strategically, Latigo is advancing its lead product candidate, onzotrigine, an oral Nav1.8 inhibitor aimed at providing non-opioid pain relief. The company recently completed a pivotal trial for onzotrigine, which met its primary endpoint, demonstrating a significant analgesic effect compared to an opioid comparator. The company plans to initiate a Phase 3 trial for onzotrigine in the second half of 2026, with topline results expected in 2027. Additionally, Latigo is developing LTG-321, another Nav1.8 inhibitor, which is currently in a Phase 2 proof-of-concept trial for chronic musculoskeletal pain.

Latigo's operational metrics indicate a focus on expanding its clinical pipeline and enhancing its organizational capabilities. The company has increased its employee headcount to support its development activities, which is reflected in the rise in personnel-related expenses. The company anticipates that its existing cash, along with the net proceeds from its recent IPO, will be sufficient to fund its operations into 2029. However, it acknowledges the need for additional capital to support ongoing development and commercialization efforts, emphasizing the inherent risks associated with the biotechnology sector.